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Oral controlled release (CR) systems constitute the most »sought after« route of
drug administration since they obviate the need of frequent dosage administration and
fluctuating blood levels characterized by saw-tooth kinetics, and hence improve the pa-
tient compliance (1). The success of CR devices is invariably hindered by their inability
to localize in the selected region(s) of the gastrointestinal (GI) tract (2). Mucoadhesive
drug delivery systems (DDS) offer a promising approach for controlled and site-specific
delivery to the GI tract by attaching the devices to the mucus and mucosa of the tract via
the process of bioadhesion. These mucoadhesive systems are also known to provide inti-
mate contact between the dosage form and the absorptive mucosa, resulting in high drug
flux through the absorbing tissue with improved bioavailability (3).
Hydralazine (HZ), a directly acting vasodilator, is widely prescribed in the treatment
of hypertension and congestive heart failure. Albeit the drug is readily absorbed follow-
ing oral administration, it is subjected to significant first-pass metabolism (4). Oral bio-
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availability of the drug has been reported to range between 10 and 35 %, depending upon
the extent of acetylation. HZ has a short biological half-life (2–4 h), low dose (50–100 mg)
and high physicochemical stability. Owing to these favorable properties, several researchers
have reported once-a-day CR formulation of HZ (5–8). No attempts, however, have been
reported to date on formulation optimization of its CR bioadhesive system.
The objective of the current study was to develop mucoadhesive CR tablet formula-
tions of HZ hydrochloride and optimize their bioadhesive and drug release characteris-
tics employing the benefits of the 'Design of Experiments' (DoE) methodology (9).
EXPERIMENTAL
Chemicals and reagents
HZ hydrochloride was provided ex gratis by M/s Sarabhai Chemicals Ltd., India.
Methocel K4M (hydroxypropylmethyl cellulose, HPMC) and Carbopol 971P (CP) were
obtained as gift samples from M/s Dow Chemical Company, USA and M/s B.F. Good-
rich Ltd., USA, respectively. Dibasic calcium phosphate (CaHPO4, DCP) and magnesium
stearate (MS) were obtained from M/s Namco Laboratories, India and Loba Chemie Ltd.,
India, respectively. All other materials used in the current study were of analytical grade
and were used as received.
Formulation
Different mucoadhesive tablet formulations of HZ hydrochloride were formulated
using varying amounts of polymers (CP and HPMC) and DCP as the inert diluent, along
with a fixed quantity of MS as the glidant and lubricant. Table I lists the various compo-
sitions employed during the study. HZ hydrochloride and the polymers, viz., CP and
HPMC, were screened through a # 80 mesh sieve (size: 180 mm) and DCP and MS were
screened through a # 120 mesh sieve (size: 125 mm) prior to use. All materials were accu-
rately weighed and mixed intimately in a polyethylene bag for 10 minutes. The blended
mix was subsequently compressed into 400 mg tablets using flat-faced and round pun-
ches (12.8 mm diameter) fitted in a single-punch manual compression machine (Cadmach,
India).
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Experimental design
A central composite design (CCD) for two factors at three levels each (with a = 1)
was selected to optimize the varied response variables. The two factors, viz. polymer X1
(CP) and polymer X2 (HPMC) of each polymer blend, were varied as required by the ex-
perimental design and the factor levels were suitably coded (Table II). The amount of
MS was kept constant at 1.25 % (m/m), while DCP was taken in a sufficient quantity to
maintain a constant tablet mass of 400 mg. Time taken to release 50 % of the drug (t50),
extent of release until 18 hours (ext18), diffusional release exponent (n), and bioadhesive
strength (r) were taken as the response variables.
Tablet assay and physical evaluation
Ten tablets were powdered and a quantity equivalent to 20 mg of HZ hydrochloride
was extracted with 60 mL of methanol. The resultant suspension was heated at 60 °C
and shaken for 15 minutes. The contents were cooled and diluted up to 100 mL with
methanol and filtered. Absorbance of the filtrate was measured at lmax of 265 nm using
a double beam UV/Vis spectrophotometer (140 A, Shimadzu, Japan) and the drug con-
tent was determined using the standard calibration equation taking the molar absorp-
tion coefficient (e) as 1.0107 ´ 104 L mol–1 cm–1. Tablets were also evaluated for hardness
(n = 6) using a Monsanto type hardness tester (Campbell, India), friability (n = 6) using a
Roche Friabilator (Tropical Lab Equipments, India), mass variation (n = 10) using an
electronic balance (Mettler, Switzerland), and thickness (n = 10) using Vernier Callipers
(Baker Gauges Ltd., India).
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Table II. Factor combinations as per the chosen experimental design
Formulation code Trial No.
Coded factor levels
X1 X2
F1 1 –1 –1
F2 2 –1 0
F3 3 –1 1
F4 4 0 –1
F5 5 0 0
F6 6 0 1
F7 7 1 –1
F8 8 1 0
F9 9 1 1
Translation of coded levels in actual units
Coded level –1 0 1
X1: CP (mg) 50 100 150
X2: HPMC (mg) 60 120 180
In vitro drug release studies
Dissolution studies were carried out on all the formulation combinations in tripli-
cate, employing the USP 27 (10) paddle method (Apparatus 2, Pharma Test, USA) at 50
rpm and 37 ± 0.5 °C using phosphate buffer (PB) pH 6.6 as the dissolution medium. An
aliquot of sample was withdrawn periodically at suitable time intervals and the volume
was replaced with an equivalent volume of plain dissolution medium. Samples were ana-
lyzed spectrophotometrically at 260 nm. Drug release data obtained from in vitro disso-
lution were analyzed using the ZOREL software (11) with in-built provisions for apply-
ing the correction factor for volume and drug losses during sampling (12). Drug release
data were fitted into the Korsemeyer-Peppas model (13):
M
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where Mt is the amount of drug released at time t, M∞ is the amount of drug released at
an infinite time, k1 and k2 are the magnitudinal contributions of diffusion and polymer
relaxation mechanism, and n is the Fickian diffusion coefficient.
Based on the phenomenological analysis, the type of release, i.e., whether Fickian,
non-Fickian (anomalous) or zero-order, was predicted. The value of t50 was calculated
using the Stineman interpolation option of the GRAPH software (Version 2, Micromath
Inc., USA). Dissolution studies employing graded concentrations of DCP and without
DCP were carried out earlier to ratify its inertness on drug release kinetics.
Ex vivo bioadhesion studies
Bioadhesion studies were conducted employing a slightly modified version of an
in-house fabricated bioadhesion assembly (3, 14). Porcine gastric mucosa was used as
the model membrane. The mucosa was kept frozen in PB pH 7.4 and thawed to room
temperature before use. The mucosal membrane was excised by removing the underly-
ing connective and adipose tissue and was equilibrated at 37 ± 1 °C for 30 min in buffer
(PB pH 6.6) before the bioadhesion evaluation study. The tablet (n = 3) was lowered onto
the mucosa under a constant weight of 49 N for a total contact period of 1 min. Bio-
adhesive strength was assessed in terms of weight, in N, required to detach the tablet
from the membrane.
Bioadhesive strength of the optimized formulation was also investigated as a func-
tion of pH using eight buffers (0.1 mol L–1) with pH ranging between 1.2 and 8.0.
Optimization data analysis
For the studied design, the multiple linear regression analysis (MLRA) method was
applied using the Design Expert software version 6.0.10 (Stat-Ease, USA) to fit the full
second-order polynomial equation with added interaction terms. Polynomial regression
results were demonstrated for the studied responses. Finally, the prognosis of optimum
formulation was conducted in two stages; first, a feasible space was located and second,
an exhaustive grid search was conducted to predict the possible solutions.
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DoE validation and selection of optimum formulation
Eight formulations were selected as check-points to validate DoE optimization. Mu-
coadhesive tablet formulations were compressed using the chosen optimal composition
and evaluated for physical tests, tablet assay, dissolution performance and bioadhesion,
as described earlier. The observed and predicted responses were critically compared. Li-
near correlation plots were constructed for the eight chosen optimized formulations. Re-
sidual graphs between predicted and observed responses were also constructed sepa-
rately and the percent bias (error) was calculated with respect to the observed responses.
Amongst the formulations selected for validation (n = 8) and prepared as per the experi-
mental design (n = 9) one was carefully chosen as the optimum formulation by »trading
off« the values of response parameters. Values of t50, ext18, r and n were maximized within
the available domain.
RESULTS AND DISCUSSION
Selection of polymers and suitable experimental design
The polymers, viz. CP and HPMC, were selected owing to their excellent bioadhe-
sive strength, release rate controlling ability (15), non-toxicity, non-irritancy, stability at
GI pH and compatibility with the drug. Successful use of the polymer combination of an
ionic polymer (like CP) and a nonionic polymer (like HPMC) is known to provide the
formulation with controlled drug release along with desired mucoadhesive properties
(14, 16).
A CCD for two factors at three levels with a = 1, equivalent to 32 factorial design
(FD), was chosen as the experimental design. This is an effective second-order experi-
mental design associated with a minimum of experiments to estimate the influence of
individual variables (main effects) and their second-order effects (14, 17 18). Further, this
design has an added advantage of determining the quadratic response surface, not esti-
mable using an FD at two levels (19).
Drug content and physical evaluation
The content of drug in formulations varied between 98.5 and 100.2 % (m/m) (mean
± SD = 99.3 ± 0.7 %). Tablet mass varied between 399.09 and 403.06 mg (401.08 ± 1.62 mg),
thickness between 2.51 and 2.91 mm (2.71 ± 0.17 mm), hardness between 4.67 and
7.04 kg cm–2 (5.86 ± 1.16 kg cm–2), and friability ranged between 0.51 and 0.76 % (m/m)
(0.64 ± 0.12 %). Thus, all physical parameters of the compressed matrices were within
the permissible limits of USP (10).
In vitro drug release studies
Addition of either water-soluble or insoluble diluents in large quantities can mark-
edly increase the release rate of hydrosoluble active principles (20). Preliminary studies
carried out at graded DCP levels, viz., 1:1, 1:3 and 1:5, and without DCP indicated near
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superimposability in the dissolution curves with values of the similarity factor (f2) rang-
ing between 89.9 to 97.8 (21). This analogy of dissolution profiles ratifies the inertness of
DCP in the present drug release studies.
As evident from the diverse nature of dissolution profiles (Fig. 1), the influence of
polymer levels seems to be vital in regulating the drug release. Drug release rate curves
(Fig. 1, inset) of all the formulations portray an initial burst release of the drug, charac-
teristic of most hydrophilic matrices (3, 14, 22). Summary of the drug release parameters
(Table III) shows that the value of n varies from 0.4653 to 0.6618, distinctly delineating
the non-Fickian release behaviour of all formulations. Values of the kinetic constant, k,
showed a declining trend with an increase in the level of each polymer, construing an
appreciable change in the polymer matrix with a change in the polymer composition.
Relatively high magnitudes of the Fickian diffusion constant, k1, vis-à-vis the polymer re-
laxation constant, k2, clearly show that the drug release was predominantly determined
by Fickian diffusion, with negligible contribution of polymer relaxation. This is in conso-
nance with several research findings that a mixture of HPMC with CP results in the re-
duction of polymer viscosity owing to reduced hydration of the matrix and facilitating
drug diffusion through the polymer hydrogel (14, 16, 23, 24). Table III reveals that the
overall rate of drug release tended to decrease with an increase in concentration of HPMC
or CP. The values of t50 were found to rise markedly from 3.49 to 18.11 h from the lowest
to the highest level of both polymers, respectively. In contrast, the values of ext18 de-
creased significantly with an increase in the content of either polymer. Nearly 50 % of
the drug remained captive in the hydrophilic matrix up to 18 hours at the highest levels
of both polymers, which may lead to appreciable diminution in the extent of drug ab-
sorption. Moderate levels of polymers should, therefore, be employed to yield an apt
value of t50 and ext18.
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Fig. 1. Dissolution profiles of various mucoadhesive tablet formulations (F1 to F9) of hydralazine
hydrochloride prepared as per the experimental design (n = 3). The crossbars indicate ± 1 SD. The
inset shows the corresponding drug release rate profiles.
Ex vivo bioadhesive strength determination
Fig. 2 construes an increasing trend in the bioadhesive strength with an increased
amount of either polymer, in agreement with the literature (3, 14, 25). Hydrogels are known
to swell readily on contact with the hydrated mucous membrane (14). This glass-rub-
bery transition provides hydrogel plasticization, resulting in a large adhesive surface for
maximum contact with mucin and flexibility to the polymer chains for interpenetration
with mucin. Increasing the polymer amount may provide more adhesive sites and poly-
mer chains for interpenetration with mucin, resulting in augmentation of bioadhesive
strength. Although the maximum value of bioadhesive strength is attained at the high-
est levels of both polymers, the effect of CP was found to be distinctly more pronounced
than that of HPMC.
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Table III. Drug release parameters of various mucoadhesive formulations prepared as


































F1 50 60 0.4653 0.271 1.334 –0.0052 93.71 3.49 3.68 ± 3.31
F2 50 120 0.5331 0.208 1.240 0.0088 87.73 4.64 3.31 ± 2.53
F3 50 180 0.6092 0.165 1.172 0.0226 83.45 5.01 3.62 ± 2.52
F4 100 60 0.6017 0.166 1.179 0.0206 88.25 5.47 3.11 ± 2.03
F5 100 120 0.5433 0.182 1.202 0.0113 84.51 5.81 2.94 ± 2.22
F6 100 180 0.5131 0.165 1.777 0.0076 70.87 8.03 2.52 ± 2.16
F7 150 60 0.6618 0.103 1.093 0.0239 64.40 10.24 2.48 ± 1.55
F8 150 120 0.5607 0.125 1.129 0.0118 61.99 11.33 2.13 ± 1.53
F9 150 180 0.5041 0.121 1.130 0.0037 49.71 18.11 1.72 ± 1.47
a Mean ± SD; n = 3
Formulation code

























Fig. 2. Bar diagram showing bioad-
hesive strength determined as the
force of detachment of mucoadhesi-
ve tablet formulations (F1 to F9) of
hydralazine hydrochloride prepared
as per central composite design (n
= 3). The crossbars indicate + 1 SD.
The bioadhesive strength tends to rise uptill pH 5 and reaches almost plateau levels
thereafter. The results are in agreement with earlier reports that optimum gel strength-
ening of mucoadhesive polymers occurs in weakly acidic environments, where both the
polymer and the mucus have their optimum spatial conformation and thereby, impro-
ved viscoelasticity (26). Thus, it can be concluded that the optimized formulation has a
distinct bioadhesive potential throughout the pH environment of the GI tract. Such opti-
mized mucoadhesive tablets offer an economical and simpler technology as a once-a-
-day GI retentive CR formulation system of the drug.
Exploration of polymer mechanism using RSM
Quite high values of R2 of the MLRA coefficients for all four responses, ranging be-
tween 0.9946 and 0.9999, vouch high prognostic ability of the RSM polynomials:
Y = bo + b1X1 + b2X2 + b3X1X2 + b4X12 + b5X22 + b6X1X22 + b7X2X12
Seven coefficients (b1 to b7) were calculated representing b0 as the intercept, and b3 to b7
various quadratic and interaction terms.
Figs. 3a to 6a portray the 3-dimensional response surface plots for the studied re-
sponse properties, viz., t50, ext18, r and n while Figs. 3b to 6b depict the corresponding
contour plots. Fig. 3a shows a nonlinear trend in the values of t50, markedly increasing
with the augmentation of CP levels. With HPMC, the values of t50 tend to rise nonli-
nearly, followed by an asymptote at the low levels of CP. The same is evident from the
corresponding contour plot (Fig. 3b), showing somewhat declining nonlinear contour lines.
Figs. 4a and 4b reveal a sharp decline in the value of ext18 with an increase in the amount
of each of the polymers, i.e., CP and HPMC, the influence of CP being much more pro-
nounced. Nonlinear descending contour lines in Fig. 4b further show that the variation
in ext18 is a complex function of the polymer levels, the effect of HPMC being less prom-
inent. Fig. 5a shows a nearly linear ascending pattern for the values of bioadhesive strength,
as the content of either polymer is increased, the effect being much more prominent with
CP than with HPMC. Maximum bioadhesive strength is observable at the highest levels
8
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Fig. 3. a) Response surface plot showing the influence of CP and HPMC on the value of t50 of mucoadhesive
tablet formulations of hydralazine hydrochloride; b) the corresponding contour plot.
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Fig. 4. a) Response surface plot showing the influence of CP and HPMC on the value of the extent
of drug release up to 18 h (ext18) of mucoadhesive tablet formulations of hydralazine hydrochlo-

































Fig. 5. a) Response surface plot showing the influence of CP and HPMC on the value of bioadhesive






































Fig. 6. a) Response surface plot showing the influence of CP and HPMC on the value of the release
exponent (n) of mucoadhesive tablet formulations of hydralazine hydrochloride; b) the correspond-
ing contour plot.
of both polymers, viz., CP and HPMC. Nearly vertical contour lines (Fig. 5b) corroborate
the markedly significant influence of CP on r values vis-a-vis HPMC. Fig. 6a portrays a
twisted nonlinear relationship of n with increasing amounts of HPMC and CP. At low
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Mean (± SD) percent 0.3 ± 1.8
HPMC levels, the value of n increases nonlinearly with an increase in CP. On the other
hand, the value of n at low levels of CP increases to an asymptote with an increasing
amount of HPMC. Thus, the current results seem to be in agreement with the findings of
Nokhodchi et al. (24), indicating an ambiguous relationship of n with the change in poly-
mer composition. The corresponding contour plot (Fig. 6b) also shows an unambiguous
nonlinear trend with a »saddle point« at the low levels of CP and high levels of HPMC
(9).
DoE validation and selection of optimum formulation
Upon comparison of the observed responses with those of the anticipated ones (Ta-
ble IV), the prediction error varied between –3.2 and 4.2 % (mean ± SD = 0.32 ± 1.8 %).
Linear correlation plots drawn between the predicted and observed responses after forc-
ing the line through the origin, also demonstrated high values of R (0.9771 to 0.9989), in-
dicating excellent goodness of fit (p < 0.001). The corresponding residual plots show ne-
arly uniform and random scatter around the mean values of response variables.
The optimum formulation was selected by »trading off« various response variables
and adopting the following maximizing criteria: t50 > 4.5 h; ext18 > 80; 0.57 < n < 0.89;
r > 235.2 N. Upon comprehensive evaluation of grid searches, the formulation (CP: 50.0 mg
and HPMC: 68.4 mg) fulfilled the optimal criteria of best regulation of the release rate
and bioadhesive strength with t50 of 5.29 h, ext18 of 91.51 %, n of 0.6302 and r of 254.9 N.
CONCLUSIONS
The current studies are aimed at successful development and optimization of a
once-a-day formulation of HZ hydrochloride with high regulation of the release rate and
bioadhesive strength. Suitable balancing between the levels of two polymers (CP and
HPMC) is imperative to acquire maximum extension in drug release and adequate bio-
adhesion. The bioadhesive nature of formulation may prolong the GI retention in an ac-
tual in vivo situation and eventually augment the extent of release and absorption. Mi-
niscule bias between the observed and predictive responses confirms the high prognostic
ability of the study design. The study offers a platform technology, the results of which
can be successfully extrapolated to the soluble salts of other basic drugs as well.
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S A @ E T A K
Razvoj tableta hidralazina s kontroliranim osloba|anjem za oralnu uporabu:
Optimizacija osloba|anja ljekovite tvari i bioadhezivnih svojstava
BHUPINDER SINGH, SONIA PAHUJA, RISHI KAPIL i NAVEEN AHUJA
Istra`ivanje uklju~uje razvoj bioadhezivnih hidrofilnih matriksa hidralazin hidroklo-
rida za oralnu uporabu, optimizaciju osloba|anja ljekovite tvari in vitro i bioadhezivnih
svojstava ex vivo na sluznici `eluca svinje. 32 dizajniranje kori{teno je za sistematsko op-
timiranje formulacija koje u sastavu imaju dva polimera, karbomer i hidroksipropilme-
tilcelulozu. Nacrtane su krivulje ovisnosti i grubo odabrane optimalne formulacije. Vali-
dacija optimiranih formulacija ukazuje vrlo visoki stupanj predvidljivosti. Razvijena je
optimirana formulacija hidralazina koja se dozira jednom dnevno, a ima izvrsnu bioad-
hezivnost i sposobnosti kontroliranog osloba|anja.
Klju~ne rije~i: hidralazin, dizajniranje eksperimenta, bioadhesivnost, metoda povr{ina, gastrointes-
tinalni terapijski sustav, hidrofilni matriksi
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